Infectious disease
Moderna signed a contract worth up to $1.525 billion with the U.S. government to supply 100 million doses of mRNA-1273, the company’s experimental COVID-19 vaccine.
Simon Fraser University chemist Robert Britton and a team of international researchers believe that their findings could lead to a more efficient way of discovering drugs for newly evolved viruses as well, such as the SARS-CoV-2 (COVID-19).
The government of Russia has approved a vaccine for COVID-19, marking the first preventative treatment for the novel coronavirus.
Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe COVID-19 infections.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
They are approximately 25% of the size of human antibodies and from other animals, and they appear to be the most potent anti-coronavirus compound that has been tested in the laboratory so far.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising.
Novavax said the agreement will allow for the development and distribution of NVX‑CoV2373, a recombinant vaccine engineered from the genetic sequence of SARS-CoV-2, in India and in low- and middle-income countries.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.
PRESS RELEASES